K K Kang

Summary

Affiliation: Research Laboratories
Country: Korea

Publications

  1. ncbi Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159
    T Y Oh
    Research Laboratories, Dong A Pharm Co, Ltd, Yongin, Kyunggi, Korea
    Arch Pharm Res 23:471-6. 2000
  2. ncbi The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction
    K K Kang
    Research Laboratories of Dong A Pharmaceutical Company, Preclinical Division, Sangal, Kiheung, Youngin, Kyunggi, Republic of Korea
    Int J Impot Res 17:409-16. 2005
  3. ncbi Ejaculatory responses are inhibited by a new chemical entity, DA-8031, in preclinical rodent models of ejaculation
    Kyung Koo Kang
    Research Institute of Dong A Pharmaceutical company, 47 5 Sang gal, Ki heung, Yong In, Kyoung gi, 446 905, South Korea
    Urology 81:920.e13-8. 2013
  4. ncbi DA-8159, a new PDE5 Iihibitor, induces penile erection in conscious and acute spinal cord injured rabbits
    Kyung Koo Kang
    Research Laboratories of Dong A Pharmaceutical Company, 47 5 Sanggal, Kiheung, Youngin, Kyunggi, 449 900 South Korea
    Eur Urol 43:689-95. 2003
  5. ncbi DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats
    Kyung Koo Kang
    Research Laboratories, Dong A Pharm Co Ltd, 47 5, Sanggal, Kiheung, Yongin, Kyunggi 449 905, Korea
    Arch Pharm Res 26:612-9. 2003
  6. ncbi Safety evaluation of GX-12, a new HIV therapeutic vaccine: investigation of integration into the host genome and expression in the reproductive organs
    Kyung Koo Kang
    Research Laboratories, Dong A Pharmaceutical Co Ltd, Yongin Shi, Kyunggi Do, Korea
    Intervirology 46:270-6. 2003
  7. ncbi Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis
    G J Ahn
    Research Laboratory, Dong A Pharmaceutical Company, Kiheung, Yongin, Kyunggi 446 905, Korea
    Asian J Androl 11:435-42. 2009
  8. ncbi DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension
    K K Kang
    Research Institutes, Dong A Pharmaceutical Co Ltd, Sanggal, Kiheung, Yongin, Kyunggi, South Korea
    J Int Med Res 31:517-28. 2003
  9. ncbi The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats
    G J Ahn
    Department of Efficacy and Toxicology, Preclinical Division, Research Laboratories, Dong A Pharmaceutical Company Ltd, Kyunggi, Republic of Korea
    Int J Impot Res 17:134-41. 2005
  10. ncbi Effect of DA-8159, a selective phosphodiesterase type 5 inhibitor, on electroretinogram and retinal histology in rabbits
    Ho Kyun Cho
    Department of Ophthalmology, Chung Ang University Medical School, Seoul, Korea
    J Korean Med Sci 19:586-90. 2004

Collaborators

  • M Yoo
  • Byoung Ok Ahn
  • C H Lee
  • Moon Koo Chung
  • Ho Kyun Cho
  • Seul Min Choi
  • G J Ahn
  • Jae Young Yu
  • Seung-Ho Lee
  • Jong Won Kwon
  • Gook Jun Ahn
  • Jong Kwan Park
  • Han Gook Jung
  • Jee Hyun Shin
  • Woo Suk Hwang
  • Sung Keun Kang
  • Byeong Chun Lee
  • Young Sung Sohn
  • Won Bae Kim
  • T Y Oh
  • H K Chung
  • Jung Sun Park
  • Sung Zoo Kim
  • Wan Shou Cui
  • Sung Won Lee
  • Sang Bong Jeon
  • Ko-Woon Kim
  • Ko Woon Kim
  • Jee Eun Kim
  • S K Kang
  • W S Hwang
  • B C Lee
  • Yong Sung Sohn
  • Dong Sung Kim
  • J W Kwon
  • Mi Jung Seo
  • Y S Sohn
  • Byung Moon Kim
  • Dong Sop Lee
  • Chae Young Kim
  • Mi Kyung Son
  • W B Kim

Detail Information

Publications23

  1. ncbi Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159
    T Y Oh
    Research Laboratories, Dong A Pharm Co, Ltd, Yongin, Kyunggi, Korea
    Arch Pharm Res 23:471-6. 2000
    ..These findings suggest that DA-8159 has significant therapeutic potential in the treatment of erectile dysfunction...
  2. ncbi The effect of DA-8159, a novel PDE5 inhibitor, on erectile function in the rat model of hypercholesterolemic erectile dysfunction
    K K Kang
    Research Laboratories of Dong A Pharmaceutical Company, Preclinical Division, Sangal, Kiheung, Youngin, Kyunggi, Republic of Korea
    Int J Impot Res 17:409-16. 2005
    ..These results suggest that DA-8159 is beneficial for erectile dysfunction in a rat hypercholesterolemic model and provided a rationale for the potential use of DA-8159 for treating erectile dysfunction secondary to hypercholesterolemia...
  3. ncbi Ejaculatory responses are inhibited by a new chemical entity, DA-8031, in preclinical rodent models of ejaculation
    Kyung Koo Kang
    Research Institute of Dong A Pharmaceutical company, 47 5 Sang gal, Ki heung, Yong In, Kyoung gi, 446 905, South Korea
    Urology 81:920.e13-8. 2013
    ....
  4. ncbi DA-8159, a new PDE5 Iihibitor, induces penile erection in conscious and acute spinal cord injured rabbits
    Kyung Koo Kang
    Research Laboratories of Dong A Pharmaceutical Company, 47 5 Sanggal, Kiheung, Youngin, Kyunggi, 449 900 South Korea
    Eur Urol 43:689-95. 2003
    ..The aim of this study was to investigate the effects of DA-8159 on penile erection in conscious and acute spinal cord injured (ASCI) rabbits...
  5. ncbi DA-8159, a potent cGMP phosphodiesterase inhibitor, attenuates monocrotaline-induced pulmonary hypertension in rats
    Kyung Koo Kang
    Research Laboratories, Dong A Pharm Co Ltd, 47 5, Sanggal, Kiheung, Yongin, Kyunggi 449 905, Korea
    Arch Pharm Res 26:612-9. 2003
    ..In myocardial morphology, MCT-induced myocardial fibrosis was markedly prevented by DA-8159. These results suggest that DA-8159 may be a useful oral treatment option for PH...
  6. ncbi Safety evaluation of GX-12, a new HIV therapeutic vaccine: investigation of integration into the host genome and expression in the reproductive organs
    Kyung Koo Kang
    Research Laboratories, Dong A Pharmaceutical Co Ltd, Yongin Shi, Kyunggi Do, Korea
    Intervirology 46:270-6. 2003
    ..These findings suggest that the risk of mutation or germline transmission due to GX-12 injection is negligible...
  7. ncbi Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical diabetogenesis
    G J Ahn
    Research Laboratory, Dong A Pharmaceutical Company, Kiheung, Yongin, Kyunggi 446 905, Korea
    Asian J Androl 11:435-42. 2009
    ..Udenafil also has an inhibitory role in cGMP (cyclic guanosine monophosphate) degradation...
  8. ncbi DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension
    K K Kang
    Research Institutes, Dong A Pharmaceutical Co Ltd, Sanggal, Kiheung, Yongin, Kyunggi, South Korea
    J Int Med Res 31:517-28. 2003
    ..DA-8159 might, therefore, be a useful treatment option for PH, but its efficacy in humans needs evaluating...
  9. ncbi The effect of PDE5 inhibition on the erectile function in streptozotocin-induced diabetic rats
    G J Ahn
    Department of Efficacy and Toxicology, Preclinical Division, Research Laboratories, Dong A Pharmaceutical Company Ltd, Kyunggi, Republic of Korea
    Int J Impot Res 17:134-41. 2005
    ..87+/-2272 in diabetic group). These results suggest that subchronic treatment of DA-8159 can prevent the development of erectile dysfunction (ED), and provides a rationale for the use of DA-8159 as treatment of diabetic ED...
  10. ncbi Effect of DA-8159, a selective phosphodiesterase type 5 inhibitor, on electroretinogram and retinal histology in rabbits
    Ho Kyun Cho
    Department of Ophthalmology, Chung Ang University Medical School, Seoul, Korea
    J Korean Med Sci 19:586-90. 2004
    ..These results suggest DA-8159 has a low risk potential to the retina, but further evaluation on the visual functions in human is needed...
  11. ncbi Safety evaluation of GX-12. A new DNA vaccine for HIV infection in rodents
    Seul Min Choi
    Research Laboratories, Dong-A Pharmaceutical Co. Ltd, Kiheung, Yongin, Kyunggi, Korea
    Drug Chem Toxicol 26:271-84. 2003
    ..Furthermore, given the limitations of this study, GX-12 neither initiated nor accelerated the development of systemic autoimmune responses...
  12. ncbi Why a combined intracavernosal injection with trimix and oral sildenafil is reliable therapy in the ultrasonographic evaluation of erectile dysfunction
    Jong Kwan Park
    Department of Urology, Medical School, and Institute for Medical Sciences, Chonbuk National University, Chonbuk, Korea
    BJU Int 102:993-7. 2008
    ....
  13. ncbi Microarray analysis of gene expression profile in the corpus cavernosum of hypercholesterolemic rats after chronic treatment with PDE5 inhibitor
    Han Gook Jung
    Research Institutes of Dong A Pharmaceutical Company, 47 5 Sanggal, Kiheung, Youngin, Kyunggi 449 905, Republic of Korea
    Life Sci 80:699-708. 2007
    ..These results provide the molecular basis for understanding the pathogenesis of hypercholesterolemia-related ED and offer clues on determining the underlying action mechanism of a PDE5 inhibitor...
  14. ncbi DA-8159 reverses selective serotonin reuptake inhibitor-induced erectile dysfunction in rats
    Gook Jun Ahn
    Research Institutes, Dong A Pharmaceutical Company, Kiheung, Youngin, Kyunggi, South Korea
    Urology 65:202-7. 2005
    ..To assess the efficacy of the phosphodiesterase 5 inhibitor, DA-8159, in selective serotonin reuptake inhibitor (SSRI)-induced rat erectile dysfunction model by measuring intracavernous pressure (ICP)...
  15. ncbi Chronic treatment of DA-8159, a new phosphodiesterase type V inhibitor, attenuates endothelial dysfunction in stroke-prone spontaneously hypertensive rat
    Seul Min Choi
    Research Laboratory, Dong-A Pharmaceutical Company, 47-5 Sanggal-Ri, Yongin, Kyunggi-Do 449-900, Korea
    Life Sci 78:1211-6. 2006
    ..Therefore, pharmacological intervention aimed at attenuating an endothelial dysfunction is important and might be useful in both preventing and treating endothelial dysfunction-related complications...
  16. ncbi Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes
    Gook Jun Ahn
    Research Institutes, Dong A Pharmaceutical Company, 47 5 Sanggal, Kiheung, Youngin, Kyunggi 449 905, Korea
    Int J Androl 28:260-6. 2005
    ..55 fmol/mL, respectively, p < 0.05). These results demonstrate that chronic administration of DA-8159 could attenuate the development of the ED in diabetes and its effect is associated with an improvement in the endothelial function...
  17. ncbi The effect of DA-8159 on corpus cavernosal smooth muscle relaxation and penile erection in diabetic rabbits
    Kyung Koo Kang
    Research Institutes, Dong A Pharmaceutical Company, 47 5 Sanggal, Kiheung, Youngin, 449 900 Kyunggi, Korea
    Urol Res 32:107-11. 2004
    ..These results suggest that DA-8159 is an effective treatment for diabetic erectile dysfunction but further evaluation of the efficacy on human needs to be performed...
  18. ncbi Penile erectile responses to electric stimulation are enhanced by a new phosphodiesterase type-5 inhibitor
    Jae Young Yu
    Research Institutes of Dong-A Pharmaceutical Company, Kyunggi, Korea
    Int J Urol 12:299-304. 2005
    ....
  19. ncbi Fertility study of the new pyrazolopyrimidinone derivative DA-8159 for erectile dysfunction in rats
    Moon Koo Chung
    Toxicology Division, Korea Institute of Toxicology, Yuseong, Daejeon, Republic of Korea
    Arzneimittelforschung 54:179-86. 2004
    ....
  20. ncbi DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model
    Kyung Koo Kang
    Research Laboratories of Dong A Pharmaceutical Company, 47 5, Sanggal, Kiheung, Yongin, Kyunggi 449 900, South Korea
    Life Sci 75:1075-83. 2004
    ..These results suggest that DA-8159 may have an erectile potential for much longer than its measured half-life...
  21. ncbi Effect of Oryza sativa extract on the progression of airway inflammation and remodeling in an experimental animal model of asthma
    Seung-Ho Lee
    Research Institutes of Dong-A Pharmaceutical Company, Yongin, Kyunggi, Republic of Korea
    Planta Med 72:405-10. 2006
    ..These results indicate that DA-9201 may play an important role in attenuating the progressing of airway inflammation and remodeling and suggest the potential benefits of DA-9201 in prevention or treatment of asthma...
  22. ncbi Gastroprotective effects of DA-6034, a new flavonoid derivative, in various gastric mucosal damage models
    Seul Min Choi
    Research Laboratories, Dong A Pharmaceutical Company, 47 5 Sanggal dong, Kiheung Gu, Yongin Shi, Kyunggi do 446 905, Korea
    Dig Dis Sci 52:3075-80. 2007
    ..These results suggest that DA-6034 prevents gastric mucosal injury, and these gastroprotective activities appear to be due to the increase in the gastric defensive systems...
  23. ncbi DA-9201 shows anti-asthmatic effects by suppressing NF-kappaB expression in an ovalbumin-induced mouse model of asthma
    Seung-Ho Lee
    Research Institutes of Dong-A Pharmaceutical Company, Yongin, Korea
    Arch Pharm Res 28:1350-7. 2005
    ..These results suggest that DA-9201 may be useful for the treatment of asthma and its efficacy is related to suppression of NF-kappaB pathway...